Abstract: Methods and systems for performing T1 mapping. T1 samples are obtained from an acquisition including one or more inversion groupings. The acquisition may be designed to result in incomplete tissue magnetization recovery between inversion groupings. The acquisition may be designed for the use of non-uniform, non-180° preparatory pulses. The method may also include the combined use of data from different inversion groupings. A model is used in which fit parameters are variable dependent on the inversion grouping.

Abstract: Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

Abstract: There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.

Abstract: Described herein are various embodiments of a method and system for sleep detection. For example, in one embodiment, a method is described for automatically characterizing digitized breath sounds recorded from a subject over time as indicative of the subject being one of asleep and awake. This method comprises identify individual breathing cycles in a given segment of the recorded breath sounds; calculating one or more preset breathing cycle characteristics from the identified breathing cycles; evaluating a relative regularity of the calculated characteristics for the given segment; and upon the relative regularity satisfying a preset high regularity condition, outputting a sleep status indicator that the subject was likely asleep during the segment, otherwise outputting a wake indicator that the subject was likely awake during the segment.

Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR? primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii.

Abstract: Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia.

Abstract: The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

Abstract: A compound of formula (I) as described herein and methods and uses thereof as probes in the mass tagging of biosensors or biologically active materials for use in mass cytometry analysis of tissue samples such as in the detection, labelling and quantification of oxygen-deprived cells by using, for example, tellurophene-tagged 2-nitroimidazole.

Abstract: There is provided herein methods of treating leukemia or lymphoma in a subject in need thereof, with double negative T cells (DNTs) in combination with Interferon-?.

Abstract: A method for characterizing a brain electrical signal comprising forming a temporo-spectral decomposition of the signal to form a plurality of time resolved frequency signal values, associating each instance of the signal value with a predetermined function approximating a neurological signal to form a table of coefficients collectively representative of the brain electrical signal.

Abstract: The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract: The application relates to a composition comprising a stably integrating delivery vector, a modified mammalian thymidylate kinase (tmpk) that increases phosphorylation of a prodrug relative to phosphorylation of the prodrug by wild-type human tmpk, and a detection cassette fused to the tmpk. The application also relates to use of these compositions in methods of treatment of diseases, such as graft versus host disease and cancer.

Abstract: The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.

Abstract: A system for fluorescence-based imaging of a target includes at least one excitation light source configured to emit a homogeneous field of excitation light and positioned to uniformly illuminate a target surface with the homogeneous field of excitation light during fluorescent imaging, a power source, and a portable housing configured to be held in a user's hand during imaging. The housing contains a lens, a filter, an image sensor, and a processor. The filter is configured to permit optical signals responsive to illumination of the target surface and having a wavelength corresponding to at least one of bacterial autofluorescence and tissue autofluorescence to pass through the filter to the image sensor. The at least one excitation light is adjacent to the housing so as to be positioned between the target surface and the image sensor during fluorescent imaging.

Abstract: Various embodiments are described herein for a system, method, and device for identifying focal source locations of electrophysiological activity in an organ. The system, method and device may also be used to guide catheter ablation of the organ. An electrogram signal can be obtained from a location in the organ, and it can be determined if the electrogram is periodic and, if so, the corresponding periodicity cycle length. A plurality of peaks associated with the cycle length can be identified. The location can be identified as a focal source location when the periodicity cycle length and the plurality of peaks have focal source characteristics. Methods are also described for identifying a direction of wave propagation and identifying multiple periodicities within an electrogram signal.

Abstract: The present teachings provide a compound represented by structural formula (I-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Abstract: Various embodiments are described herein for a system and a method for obtaining samples of tissue for analysis by mass spectrometry. A region of interest can be identified in tissue using image data from a first imaging modality that is other than mass spectrometry. At least one tissue sample can be acquired using a tissue sampler from a sampling location related to the region of interest. Mass spectrum data can be generated for the acquired tissue samples using a mass spectrometer. In some embodiments. polarimetry may be used on a tissue slice, mass spectrometry may be performed on the same tissue slice and then H&E imaging may be performed on the same tissue slice.

Abstract: Various embodiments are described herein for an apparatus and a method for measuring and characterizing geometric distortions for a region of interest in images obtained using magnetic resonance. The method comprises deriving a computed set of 3D distortion vectors for a set of points within a region of interest covered by a phantom by using harmonic analysis to solve an associated boundary value problem based on boundary conditions derived from a measured set of 3D distortion vectors. The characterized image distortions may be used for various purposes such as for image correction or for shimming, for example.

Abstract: The present invention is directed to novel synthetic methods for preparing cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein.